Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

826 sites for NCT02465060

AKT1 Mutation, +91 more biomarkers

Breast Carcinoma, +3 more conditions

adavosertib, +26 more drugs

immunotherapy, +1 more type

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

2 sites for NCT02645149

ALK Fusion, +19 more biomarkers

Melanoma, +1 more condition

ceritinib, +4 more drugs

targeted therapy

Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

1 site for NCT04708054

ARAF Mutation, +47 more biomarkers

Acute Myeloid Leukemia, +2 more conditions

busulfan, +5 more drugs

cellular therapy, +1 more type

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

51 sites for NCT03190915

CBL Loss, +8 more biomarkers

Juvenile Myelomonocytic Leukemia, +1 more condition

trametinib

targeted therapy

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

1 site for NCT05168904

BRAF Mutation, +6 more biomarkers

Acute Myeloid Leukemia, +3 more conditions

CYC065

targeted therapy

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

10 sites for NCT03297606

ABL1 Fusion, +98 more biomarkers

B-Cell Non-Hodgkin Lymphoma, +2 more conditions

axitinib, +15 more drugs

immunotherapy, +1 more type

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

4 sites for NCT05054374

ARAF Mutation, +18 more biomarkers

Breast Carcinoma, +1 more condition

fulvestrant, +1 more drug

hormone therapy, +1 more type

CRAFT: The NCT-PMO-1602 Phase II Trial

4 sites for NCT04551521

AKT1 Amplification, +78 more biomarkers

Malignant Solid Tumor

alectinib, +6 more drugs

immunotherapy, +1 more type

Safety and Efficacy Study of SAR442720 in Combination With Pembrolizumab in Advanced Malignancies

17 sites for NCT04418661

BRAF D287H, +22 more biomarkers

Malignant Solid Tumor, +1 more condition

adagrasib, +2 more drugs

immunotherapy, +1 more type

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

12 sites for NCT03634982

BRAF D287H, +19 more biomarkers

Malignant Female Reproductive System Neoplasm, +2 more conditions

RMC-4630

targeted therapy

Study of ASTX029 in Subjects With Advanced Solid Tumors

15 sites for NCT03520075

ARAF Mutation, +16 more biomarkers

Malignant Solid Tumor

ASTX029

targeted therapy

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

1 site for NCT04534283

BRAF Fusion, +14 more biomarkers

Malignant Solid Tumor

abemaciclib, +1 more drug

targeted therapy